Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth

Hiba J Mustafa, Henry L Wong, Mahmoud Al-Kofahi, Malinda Schaefer, Ashwin Karanam, Michael M Todd, Hiba J Mustafa, Henry L Wong, Mahmoud Al-Kofahi, Malinda Schaefer, Ashwin Karanam, Michael M Todd

Abstract

Objective: To evaluate bupivacaine concentrations in maternal plasma and transfer into breast milk in women undergoing liposomal bupivacaine infiltration in the transversus abdominis plane after cesarean birth.

Methods: Prospective cohort study of healthy pregnant women who underwent cesarean birth at term followed by a transversus abdominis plane block using 52 mg bupivacaine hydrochloride 0.25% (20 mL) and 266 mg liposomal bupivacaine 1.3% (20 mL). Simultaneous blood and milk samples were collected in a staggered fashion, three to four samples per patient at the following timepoints after block administration: 2, 6, 12, 24, 48, 72, and 96 hours. Quantification of bupivacaine was performed by liquid chromatography-tandem mass spectrometry. Neonatal drug exposure was modeled by calculating milk/plasma area under the curve (AUC) ratios, neonatal dosage, and relative neonatal dosage of bupivacaine at each sampling time.

Results: Thirty patients were enrolled. Concentrations in breast milk peaked at 6 hours (mean 58 ng/mL), followed by constant and steady decline to low levels at 96 hours (mean 5.2 ng/mL). Maternal plasma concentrations had two peaks, first at 6 hours (mean 155.9 ng/mL) and then at 48 hours (mean 225.8 ng/mL), followed by steady decline. Milk/plasma AUC0-t ratios ranged between AUC0-2 of 0.45 (80% CI 0.38-0.52) and AUC0-96 of 0.15 (80% CI 0.14-0.17). Neonatal dosage ranged between a mean of 355.9 ng/kg at 0-2 hours and a mean of 15,155.4 ng/kg at 0-96 hours. Relative neonatal dosage was less than 1% at all time intervals. No serious adverse reactions occurred in any neonate.

Conclusion: Bupivacaine is excreted in breast milk after local infiltration of liposomal bupivacaine and bupivacaine hydrochloride mixture into transversus abdominis plane blocks after cesarean birth. Relative neonatal dosages of less than 1% (less than 10% is considered to be unlikely to be of clinical concern) suggest minimal risks for breastfeeding healthy, term neonates after the administration of this combination of local anesthetics to mothers.

Clinical trial registration: ClinicalTrials.gov, NCT03526419.

Figures

Fig. 1.. Plots of maternal plasma and…
Fig. 1.. Plots of maternal plasma and breast milk bupivacaine concentration over time for each participant.
Mustafa. Liposomal Bupivacaine Excretion in Breast Milk. Obstet Gynecol 2020.
Fig. 2.. Mean maternal plasma and breast…
Fig. 2.. Mean maternal plasma and breast milk bupivacaine concentration over time. The shaded area represents 80% CI. The dots represent observed concentrations.
Mustafa. Liposomal Bupivacaine Excretion in Breast Milk. Obstet Gynecol 2020.

References

    1. Sutton CD, Carvalho B. Optimal pain management after cesarean delivery. Anesthesiol Clin 2017;35:107–24.
    1. Lavand’homme P. Postoperative cesarean pain: real but is it preventable? Curr Opin Anaesthesiol 2018;31:262–7.
    1. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of Anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. J Pain 2016;17:131–57.
    1. Ituk U, Habib AS. Enhanced recovery after cesarean delivery. F1000Res 2018;7:F1000Res.
    1. Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg 2005;101:S62–9.
    1. Garimella V, Cellini C. Postoperative pain control. Clin Colon Rectal Surg 2013;26:191–6.
    1. Eisenach JC, Pan PH, Smiley R, Lavand'homme P, Landau R, Houle T. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 2008;140:87–94.
    1. Postpartum pain management. ACOG Committee Opinion No. 742. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e35–43
    1. Jirasiritham S, Tantivitayatan K, Jirasiritham S. Perianal blockage with 0.5% bupivacaine for postoperative pain relief in hemorrhoidectomy. J Med Assoc Thai 2004;87:660–4.
    1. Chester JF, Stanford BJ, Gazet JC. Analgesic benefit of locally injected bupivacaine after hemorrhoidectomy. Dis Colon Rectum 1990;33:487–9.
    1. Møiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002;96:725–41.
    1. Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee 2012;19:530–6.
    1. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 2011;54:1552–9.
    1. Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J 2012;32:69–76.
    1. Hu D, Onel E, Singla N, Kramer WG, Hadzic A. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig 2013;33:109–15.
    1. Hutchins J, Argenta P, Berg A, Habeck J, Kaizer A, Geller MA. Ultrasound-guided subcostal transversus abdominis plane block with liposomal bupivacaine compared to bupivacaine infiltration for patients undergoing robotic-assisted and laparoscopic hysterectomy: a prospective randomized study. J Pain Res 2019;12:2087–94.
    1. Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS, Carson L, et al. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: a prospective randomized controlled study. Gynecol Oncol 2015;138:609–13.
    1. Baker BW, Villadiego LG, Lake YN, Amin Y, Timmins AE, Swaim LS, et al. Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review. J Pain Res 2018;11:3109–16.
    1. Brusko GD, Kolcun JPG, Heger JA, Levi AD, Manzano GR, Madhavan K, et al. Reductions in length of stay, narcotics use, and pain following implementation of an enhanced recovery after surgery program for 1- to 3-level lumbar fusion surgery. Neurosurg Focus 2019;46:E4.
    1. Gasanova I, Alexander JC, Estrera K, Wells J, Sunna M, Minhajuddin A, et al. Ultrasound-guided suprainguinal fascia iliaca compartment block versus periarticular infiltration for pain management after total hip arthroplasty: a randomized controlled trial. Reg Anesth Pain Med 2019;44:206–11.
    1. Hyland SJ, Deliberato DG, Fada RA, Romanelli MJ, Collins CL, Wasielewski RC. Liposomal bupivacaine versus standard periarticular injection in total knee arthroplasty with regional anesthesia: a prospective randomized controlled trial. J Arthroplasty 2019;34:488–94.
    1. Iwanoff C, Salamon C. Liposomal bupivacaine versus bupivacaine hydrochloride with lidocaine during midurethral sling placement: a randomized controlled trial. J Minim Invasive Gynecol 2018;26:1133–8.
    1. Burnett A, Faley B, Nyirenda T, Bamboat ZM. Liposomal bupivacaine reduces narcotic use and time to flatus in a retrospective cohort of patients who underwent laparotomy. Int J Surg 2018;59:55–60.
    1. US Food and Drug Administration. Clinical lactation studies: considerations for study design guidance for industry. Available at: . Retrieved April 18, 2020.
    1. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29(suppl 1):S49–52.
    1. Armbruster DA, Tillman MD, Hubbs LM. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 1994;40:1233–8.
    1. Portillo J, Kamar N, Melibary S, Quevedo E, Bergese S. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol 2014;5:90.
    1. Bolat E, Bestas A, Bayar MK, Ozcan S, Erhan OL, Ustundag B. Evaluation of levobupivacaine passage to breast milk following epidural anesthesia for cesarean delivery. Int J Obstet Anesth 2014;23:217–21.
    1. Ortega1 D, Viviand X, Lorec AM, Gamerre M, Martin C, Bruguerolle B Excretion of lidocaine and bupivacaine in breast milk following epidural anesthesia for cesarean delivery. Acta Anaesthesiologica Scand 1999;43:394–7.
    1. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther 2016;100:42–52.
    1. Neville MC, Keller R, Seacat J, Lutes V, Neifert M, Casey C, et al. Studies in human lactation: milk volumes in lactating women during the onset of lactation and full lactation. Am J Clin Nutr 1988;48:1375–86.
    1. Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: time to unify the approach. J Hum Lact 2002;18:323–32.
    1. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14:217–40.
    1. Bennett PN, editor. Drugs and human lactation. 2nd ed Amsterdam, The Netherlands: Elsevier; 1996.
    1. Baker PA, Schroeder D. Interpleural bupivacaine for postoperative pain during lactation. Anesth Analg 1989;69:400–2.
    1. Bethea JW. Clinical anesthesia, 6th edition. Anesthes 2010;112:767–8.
    1. Thomas J, Long G, Moore G, Morgan D. Plasma protein binding and placental transfer of bupivacaine. Clin Pharmacol Ther 1976;19:426–34.
    1. Tsen LC, Tarshis J, Denson DD, Osathanondh R, Datta S, Bader AM. Measurements of maternal protein binding of bupivacaine throughout pregnancy. Anesth Analg 1999;89:965–8.
    1. Wulf H, Winckler K, Maier C, Heinzow B. Pharmacokinetics and protein binding of bupivacaine in postoperative epidural analgesia. Acta Anaesthesiol Scand 1988;32:530–4.
    1. Anderson PO, Valdés V. Variation of milk intake over time: clinical and pharmacokinetic implications. Breastfeed Med 2015;10:142–4.
    1. Committee on Gynecologic Practice. ACOG Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery [published correction appears in Obstet Gynecol. 2019 Jun;133(6):1288] [published correction appears in Obstet Gynecol. 2019 Nov;134(5):1121]. Obstet Gynecol. 2018;132(3):e120–e130.
    1. Parikh P, Sunesara I, Singh Multani S, Patterson B, Lutz E, Martin JN. Intra-incisional liposomal bupivacaine and its impact on postcesarean analgesia: a retrospective study. J Matern Fetal Neonatal Med 2019;32:966–70.
    1. Prabhu M, Clapp MA, McQuaid-Hanson E, Ona S, OʼDonnell T, James K, et al. Liposomal bupivacaine block at the time of cesarean delivery to decrease postoperative pain: a randomized controlled trial. Obstet Gynecol 2018;132:70–8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する